Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NovaRx Corporation
The primary objective of this study is to increase the overall survival of the study subjects by providing expanded access to Lucanix. Overall survival and progression-free survivals will be compared with historical controls.
The secondary objectives of this study are:
* Evaluate the best overall tumor response.
* Evaluate progression-free survival (PFS).
* Evaluate treatment toxicity.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent
≥ 18 years
Histological confirmed non-curable stage III or IV NSCLC.
Must have completed at least one (1) regimen of anti-cancer therapy.
Following frontline therapy, subjects must observe the following wash- out periods:
* Subjects with stable disease or better must have received the last anti-cancer therapy not less than five months prior to enrollment.
* Subjects with progressive disease must have received the last anti-cancer therapy at least one (1) month prior to enrollment.
All subjects who have received two (2) or more regimens of therapy must have received the last anti-cancer therapy at least one (1) month prior to enrollment.
Performance status (ECOG) ≤ 2
Absolute granulocyte count ≥ 1,500/mm3
Platelet count ≥ 100,000/mm3
Total Bilirubin ≤ 2× Upper Limit of Normal
AST and ALT ≤ 2× Upper Limit of Normal
Creatinine ≤ 2× Upper Limit of Normal
Negative pregnancy test for women of childbearing potential.
Any chemotherapy, steroid therapy, or investigational anti-cancer agent within 4 weeks of study entry.
Subjects who received prior monotherapy with Lucanix.
Symptomatic brain metastases unless treated and stable for ≥ 2 months
Known HIV positivity
Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions which, in the opinion of the investigator would compromise protocol objectives.
Prior malignancy (excluding non-melanoma carcinomas of the skin) unless in remission for ≥ 2 years
History of psychiatric disorder that would impede adherence to protocol
Pregnant or nursing women or refusal to practice contraception if of reproductive potential
Clareo Health | Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
